Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

"The School aims to enhance the way we use technology in research, food security, microbiology, ecosystem biology, sustainability and many other related areas. The School is dedicated to providing the ...

BofA Securities has recently resumed Gilead Sciences Inc (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim Cramer talked about. Jim Cramer, host of Mad Money, recently shared ...

We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim ...

BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

Polaris Global Equity Strategy highlighted stocks like Gilead Sciences, Inc. (NASDAQ:GILD), in the third quarter 2024 investor letter. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical ...